Press Releases

2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Date Title
18 April 2019 BTG plc: close period update
07 March 2019 BTG Crossing Devices are Highlighted at the CTO Summit in NY
05 March 2019 New research validates clinical value of treating Copperhead envenomation with CroFab®
14 February 2019 A Retrospective Study of Medicare claim data shows patients treated with Voraxaze® had shorter hospitalizations and lower mortality
05 February 2019 NHS England expands loco-regional treatment options for colorectal cancer patients with metastatic disease.
21 January 2019 Australian Patient Treated With DC Bead LUMI™, the first commercially available Radiopaque Drug-Eluting Bead
08 January 2019 BTG and OMNY Partner to Improve Treatment of Snake Bite Victims
21 December 2018 BTG announces National Reimbursement for TheraSphere® in France 
03 December 2018 Arizona Patients Successfully Receive the World’s First Bioconvertible IVC Filter Commercially Offer
20 November 2018 Recommended Cash Offer for BTG plc by Boston Scientific Corporation
13 November 2018 BTG plc: Interim Results 2018
07 November 2018 BTG Sentry Bioconvertible IVC Filter 2-year Study Results Show Zero Tilt, Migration, Perforation, Fracture, or Embolization
06 November 2018 EKOS™ Control Unit 4.0 simplifies treatment of blood clots
04 October 2018 BTG plc: close period update
04 October 2018 BTG plc: Directorate change
26 September 2018 BTG Announces Replacement Policy for Expired CroFab®
20 September 2018 BTG announces global launch of the ICEfx™ cryoablation system
13 September 2018 FDA Approves CroFab® Product Improvements
07 September 2018 BTG plc acquires Novate Medical Ltd.
09 August 2018 BTG receives not-approvable letter from the US FDA for ELEVAIR™
23 July 2018 OPTALYSE PE Results Published in JACC: Cardiovascular Interventions
18 July 2018 BTG plc: Annual General Meeting
21 June 2018 PERT Consortium and BTG Form Strategic Partnership
19 June 2018 Historical Financial Information Restated to US Dollars
15 June 2018 Result of FDA Advisory Committee vote on Elevair™ for the treatment of severe emphysema
11 June 2018 ELEVATE study aims to improve selection criteria and outcomes for patients with severe emphysema treated with the PneumRx™ Endobronchial Coil System
15 May 2018 BTG plc: Final Results 2018
27 April 2018 OPTALYSE PE Results Presented at Society for Cardiovascular Angiography and Interventions
27 April 2018 OPTALYSE PE Results Presented at Society for Cardiovascular Angiography and Interventions
05 April 2018 BTG plc: close period update
04 April 2018 SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program
21 February 2018 First Patient in Latin America Receives TheraSphere® Radioembolisation Treatment
06 February 2018 OPTALYSE PE Long Term Results Reinforce Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism
23 January 2018 Appointment of Non-executive Director
14 December 2017 Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® T
13 December 2017 Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® Therapy Protocols for Pulmonary Embolism
11 December 2017 Institutional Decision to Adopt Y90 TARE with TheraSphere® as first-line treatment for HCC
27 November 2017 Appointment of Non-executive Director
16 November 2017 New consensus guidelines provide specific recommendations for use of Voraxaze® in patients with dela
14 November 2017 BTG plc: Interim Results 2017
14 November 2017 Directorate change – Chief Financial Officer
06 November 2017 BTG plc: update on legal ruling
06 November 2017 BTG plc: Varithena® receives finalised category I CPT codes
09 October 2017 First patient treated with microscopic beads pre-loaded with a targeted cancer drug and visible on CT scans
05 October 2017 BTGplc acquires Roxwood Medical
05 October 2017 BTG plc: close period update
27 September 2017 Mirada Medical signs three-year software development agreement with BTG
20 September 2017 BTG plc: legal ruling
13 September 2017 Vistogard® and Voraxaze® Added to Revised Guidelines for Stocking of Antidotes in US Hospitals
21 August 2017 BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme
25 July 2017 Vancouver’s EVA Vein Care Now Offers New Varicose Vein Treatment
13 July 2017 BTG plc: Annual General Meeting
16 June 2017 ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy for Post-Thrombotic Syndrome
13 June 2017 New Study Shows Patients Treated With CroFab® Have Improved Recovery From Copperhead Envenomation
10 June 2017 New study shows IO Loop™ improves patient follow-up, engagement and satisfaction following treatment with TheraSphere®
07 June 2017 SIO announces first grants in Interventional Oncology / Immuno-Oncology research programme
22 May 2017 OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism
19 May 2017 BTG and HealthLoop collaborate on IO Loop™, an exclusive service to connect patients and interventional oncologists throughout treatment
16 May 2017 BTG plc: Final Results 2017
20 April 2017 First European Patients Treated With DC Bead LUMI™ Radiopaque Drug-Eluting Beads
06 April 2017 BTG plc: close period update
07 March 2017 SnakeBite911™ Expands Free Snake Education and Snakebite Safety App to Android Devices
07 March 2017 BTG announces CE Mark Certification for DC Bead LUMI™, the first commercially available radiopaque drug-eluting bead in the EU
27 February 2017 BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
15 February 2017 BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology
26 January 2017 New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
26 January 2017 Nouveau traitement des varices offrant une intervention non chirurgicale à effraction minimale pour les Canadiens
09 January 2017 First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® system.
05 December 2016 PneumRx® Coils included in new global clinical guidelines and given positive recommendation to treat severe emphysema patients in France
05 December 2016 Le Canada, premier pays à bénéficier d’une nouvelle option de traitement contre le cancer du foie
15 November 2016 BTG plc: Interim Results 2016
19 October 2016 First patient in Malaysia receives TheraSphere™ radioembolisation therapy
14 October 2016 BTG and Mirada Medical announce CE Mark Certification for Simplicit90Y™ dosimetry software in Europe

New easy-to-use software designed to improve the planning of 90Y selective internal radiation therapy (SIRT) treatment for patients with liver cancer
06 October 2016 BTG plc: close period update
06 October 2016 BTG: settlement of US government investigation into LC Bead®
09 September 2016 BTG launches BETA™ Radiation Safety Programme, to reduce the risk of radiation exposure for healthcare professionals and patients
23 August 2016 BTG receives Health Canada approval for DC Bead LUMI™

First commercially available radiopaque drug-eluting bead in Canada that provides real-time visible confirmation of bead location during embolization for the treatment of tumours in patients with HCC and mCRC
17 August 2016 CMS Grants Vistogard® New Technology Add-on Payment Status Effective 1 October 2016
02 August 2016 BTG announces successful CE Mark reclassification for DC Bead® to Class III based on its ability to administer medicines
27 July 2016 BTG plc: Appointment of Non-executive Director
14 July 2016 BTG plc: Annual General Meeting
06 July 2016 Varithena® Earns FDA Approval for 30 Day Post-Activation Shelf Life
15 June 2016 BTG completes the acquisition of Galil Medical
09 June 2016 BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients
02 June 2016 BTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular Carcinoma
26 May 2016 New study highlights potential cost savings using Y90 glass microspheres in hcc
17 May 2016 BTG plc: Final Results 2016
06 May 2016 BTG plc acquires Galil Medical, a leader in cryoablation
05 April 2016 Patients with colorectal liver metastases gain wider access to unique benefits of yttrium-90 internal radiation therapy in the Netherlands
05 April 2016 BTG plc: Close Period Update
02 April 2016 BTG to initiate multi-centre TARGET study
01 April 2016 BTG announces US launch of LC Bead LUMI™
10 March 2016 BTG International Canada Expands Operations To Directly Sell Interventional Oncology Products
09 March 2016 New Data from Largest Prospective Study on CroFab® for Treatment of Copperhead Snake Envenomation
03 February 2016 First Patient Treated With LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance
26 January 2016 First Patients in South Korea Receive TheraSphere® Radioembolisation Treatment
20 January 2016 BTG Announces Presentation of New Vistogard® (uridine triacetate) Data at American Society of Clinic
14 December 2015 BTG announces FDA clearance for LC Bead LUMI™, the first commercially available radiopaque embolic bead in the US
14 December 2015 BTG Announces Positive Data from RENEW study of PneumRx® Coils
11 December 2015 BTG Announces FDA Approval of VISTOGARD® (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine
12 November 2015 BTG plc: Interim Results 2015 - Replacement
10 November 2015 BTG plc: Interim Results 2015
12 October 2015 BTG and MIRADA collaborate to develop dosimetry software solutions to optimise radioembolisation therapy in interventional oncology
06 October 2015 BTG plc: close period update 2015
27 September 2015 BTG announces positive safety and efficacy data in over 500 DC BeadM1™ patients & compelling health economic data for TheraSphere®
10 September 2015 BTG Announces FDA Acceptance of Wellstat Therapeutics’ New Drug Application for Uridine Triacetate as Antidote to Overexposure to Chemotherapy Drug 5-Fluorouracil (5-FU)
09 September 2015 BTG strides through Trekfest challenge for cancer charity
26 August 2015 BTG steps up to the Trekfest challenge for cancer charity
24 August 2015 Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions
06 August 2015 Health Canada approves Varithena™ (polidocanol injectable foam) for patients with varicose veins
15 July 2015 BTG plc: Annual General Meeting
09 July 2015 Randomized Controlled Multi-Center Trial Demonstrates Reduced Treatment Time and Drug Dose with EKOS™ vs. Catheter-Directed Thrombolysis in Peripheral Arterial Occlusions
15 June 2015 BTG plc: Annual Report and Accounts 2015
10 June 2015 First Patient in Singapore Treated with TheraSphere® Radioembolization Therapy
19 May 2015 REVOLENS study of PneumRx® endobronchial coils in severe emphysema meets primary endpoint
19 May 2015 BTG plc launches a Level 1 ADR programme
19 May 2015 BTG plc: Final Results 2015
02 April 2015 BTG plc: close period update
01 April 2015 BTG begins sale of DC Bead® and Bead Block® directly to Physicians
05 February 2015 BTG plc updates revenue guidance and ceases publication of interim management statements
08 January 2015 BTG plc: Completion of the acquisition of PneumRx Inc
19 December 2014 BTG plc: Appointment of Non-executive Director
04 December 2014 Acquisition of PneumRx
11 November 2014 BTG plc: Interim Results
13 October 2014 BTG to supply DC Bead® and Bead Block® directly to physicians in Europe from 1 April 2015
10 October 2014 BTG reaches settlement regarding CroFab® patent litigation
06 October 2014 BTG plc: Close Period Update
25 September 2014 BTG plc: Directorate Change
28 August 2014 BTG and SciClone Announce that DC Bead® has been approved by China Food and Drug Administration
11 August 2014 First Varicose Vein Patient Treated with FDA-Approved Varithena® (polidocanol injectable foam) 1%
16 July 2014 BTG plc: Interim Management Statement and Annual General Meeting
11 June 2014 EKOS Initiates a Pivotal New Study in Patients with Chronic Deep Vein Thrombosis and Post-Thrombotic Syndrome
11 June 2014 EKOS™ Initiates a Pivotal New Study in Patients with Chronic Deep Vein Thrombosis and Post-Thrombotic Syndrome
03 June 2014 BTG participates in the Trekfest Challenge
23 May 2014 EkoSonic™ Endovascular System receives FDA Clearance for theTreatment of Pulmonary Embolism in the USA
23 May 2014 EkoSonic® Endovascular System receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA
20 May 2014 BTG plc: Final Results 2014
06 May 2014 BTG becomes a major supporter of ESIRonline, CIRSE’s online educational database for Interventional Radiologists
03 April 2014 BTG plc: Close period update
30 March 2014 Acute Pulmonary Embolism Trial Confirms Safety and Efficacy of Ultrasound Accelerated Endovascular Thrombolysis
21 February 2014 BTG announces Varithena™ data demonstrating continued improvement at one year at the American Venous Forum Annual Meeting
29 January 2014 BTG plc: Interim Management Statement
20 January 2014 Pulmonary Embolism Trial Comparing Endovascular Ultrasound to Standard of Care Anticoagulation Published in the American Heart Association’s Journal, Circulation
08 January 2014 BTG’s manufacturing facility in west Wales awarded top Environmental Standard
07 January 2014 BTG to present at the 32nd Annual J.P. Morgan Healthcare Conference
26 November 2013 BTG plc: FDA approves Varithena™ (polidocanol injectable foam) for the treatment of patients with varicose veins
18 November 2013 BTG to present at Jefferies Global Healthcare Conference
12 November 2013 BTG plc: Interim Results
25 October 2013 BTG plc: Notification of Results
03 October 2013 BTG plc: Close Period Update
18 September 2013 BTG plc: European Commission Approves Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)
17 September 2013 BTG sells brachytherapy business to Eckert & Ziegler
30 July 2013 TheraSphere® Recommended by the National Institute for Health and Care Excellence (NICE) for the Treatment of Primary and Secondary Liver Cancer
25 July 2013 BTG Announces Positive Results from VANISH-2 Study Data Published in the Journal Phlebology
16 July 2013 BTG plc: Interim Management Statement
15 July 2013 BTG PLC announce the completion of acquisition of Therasphere®
08 July 2013 BTG PLC acquisition of EKOS
28 June 2013 Receives Positive CHMP Opinion for LEMTRADA™ (alemtuzumab) in Europe
21 June 2013 BTG plc: Publication of Circular and Notice of General Meeting
03 June 2013 BTG to Present at the Jefferies Global Healthcare Conference
28 May 2013 BTG to Present at the 38th Annual Deutsche Bank Health Care Conference
23 May 2013 BTG plc: Results of Placing
23 May 2013 BTG PLC proposed acquisition of Therasphere®
23 May 2013 BTG PLC acquisition of EKOS
23 May 2013 BTG plc: Proposed Placing or Ordinary New Shares
20 May 2013 BTG plc: Final Results
03 May 2013 The BTG Cycle Challenge 2013
12 April 2013 BTG plc: Varisolve® NDA accepted for full review by FDA
04 April 2013 BTG plc: Close Period Update
21 February 2013 BTG to Present at the Citi Global Healthcare Conference
04 February 2013 BTG plc: Varisolve® NDA submitted to the FDA
31 January 2013 BTG plc: Interim Management Statement
07 January 2013 BTG to present at the 31st Annual J.P. Morgan Healthcare Conference
11 December 2012 BTG plc: US FDA approves expanded ZYTIGA® indication for treatment of metastatic castration-resistant prostate cancer
20 November 2012 BTG plc: Janssen announces that ZYTIGA® has received a positive opinion in the EU for treating chemo-naïve mCRPC patients
19 November 2012 Full data from pivotal Phase III trials of Varisolve® PEM presented at the 26th Annual Congress of the American College of Phlebology
12 November 2012 BTG plc: Appointment of Non-executive Director
23 May 2012 BTG plc: Results of Placing
21 May 2012 BTG plc: Final Results
30 April 2012 Voraxaze® (glucarpidase) Launched in the US
23 April 2012 BTG Announces Positive Results from Second US Pivotal Phase III Trial of Varisolve®
04 April 2012 BTG plc: Close Period Update
28 March 2012 DigiFab® 40 mg/vial digoxin immune Fab
08 March 2012 BTG plc: ZYTIGA® (abiraterone acetate) second Phase III trial unblinded
20 February 2012 BTG to present at the Citi Global Health Care Conference
14 February 2012 BTG plc: Directorate Change Amendment
30 January 2012 BTG Announces Positive Data from First US Phase III Trial of Varisolve®
25 January 2012 BTG plc: Interim Management Statement
18 January 2012 BTG plc: Voraxaze® (glucarpidase) receives US regulatory approval
11 January 2012 BTG to present at the 30th Annual J.P. Morgan Healthcare Conference
07 December 2011 BTG plc: Voraxaze® (glucarpidase) licensed to Ohara Pharmaceuticals in Japan
17 November 2011 BTG plc: Interim Results
11 November 2011 Garry Watts to succeed Dr John Brown as non-executive Chairman
01 November 2011 BTG plc: Directorate Change
05 October 2011 BTG plc: Close Period Update
20 September 2011 BTG plc: FDA accepts Biologics License Application file for Voraxaze® (glucarpidase) and grants Priority Review
07 September 2011 BTG plc: ZYTIGA™ (abiraterone acetate) approved in the EU
20 July 2011 BTG plc: Annual General Meeting and Interim Management Statement
11 July 2011 Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada™) in Multiple Sclerosis Reported
25 May 2011 BTG plc: Final Results
13 May 2011 AstraZeneca ends CM-3 development and option agreement
03 May 2011 BTG plc: ZYTIGA™ (abiraterone acetate) Approved in the US
05 April 2011 BTG plc: Close Period Update
11 March 2011 BTG plc: DEFEND-1 study of otelixizumab in type 1 diabetes did not meet primary endpoint
28 January 2011 Offer Update: Admission of New BTG Shares
27 January 2011 BTG plc: Interim Management Statement
27 January 2011 Offer Update: Scheme Effective
24 January 2011 Offer Update: Court sanction of the Scheme of Arrangement and timetable update
06 January 2011 Offer Update: Result of BTG Shareholder Meeting
06 January 2011 BTG to present at the J.P. Morgan Annual Healthcare Conference
21 December 2010 BTG plc: New Drug Application Submitted in the US and Marketing Authorisation Application Filed in the EU for Abiraterone Acetate
10 December 2010 Offer update: Posting of Scheme Document
29 November 2010 BTG plc: Appointment of Non-executive Director
19 November 2010 Recommended acquisition by BTG plc of Biocompatibles International plc
04 November 2010 BTG plc: Interim Results
25 October 2010 BTG plc: AstraZeneca initiates Phase IIb study for AZD9773 (CytoFab™) as a treatment for severe sepsis
15 October 2010 BTG plc: Genzyme reports positive data on alemtuzumab
16 September 2010 BTG plc: First Varisolve® US Phase III Trial Initiated
10 September 2010 BTG plc: Abiraterone Acetate Meets Pre-Determined Criteria in Metastatic Prostate Cancer Study
31 August 2010 BTG plc: Agreement with Nycomed US Inc.
13 July 2010 BTG plc: Annual General Meeting and Interim Management Statement
21 May 2010 BTG plc: Preliminary Results
01 April 2010 BTG plc: Close Period Update
04 February 2010 BTG Receives First European Regulatory Approval for DigiFab™
21 January 2010 BTG Commences Phase IIa Study of Pleneva™ for Multiple Sclerosis
21 January 2010 BTG plc: Interim Management Statement
18 December 2009 BTG Licenses ReGel® to Allergan for use in diseases of the eye
05 November 2009 BTG plc: Interim Results
24 September 2009 BTG plc: Campath® Meets Primary Endpoint in Phase III Combination Therapy Trial for Chronic Lymphocy
28 August 2009 BTG Sells HySolv™ Technology to Major Pharmaceutical Company
17 August 2009 BTG Collaborator Onyx Gains Approval to Progress Oncology Compound into Clinical Development
29 July 2009 BTG plc: AstraZeneca to Progress CytoFab™ into Phase IIb Study
15 July 2009 BTG plc: Annual General Meeting and Interim Management Statement
14 May 2009 BTG plc: Preliminary Results
02 April 2009 BTG plc: Close Period Update
22 January 2009 BTG plc: Interim Management Statement

About BTG

Businesses

Legal

Imagine where we can go.

© 2018 BTG International Ltd. All rights reserved. “Imagine where we can go.”, BTG and the BTG roundel logo are trademarks and/or registered trademarks of BTG International Ltd. Bead Block, DC Bead, DC BeadM1, DC Bead LUMI, LC Bead, LC BeadM1, LC Bead LUMI, LUMI, Simplicit90Y, IO Loop and IO Ablation are trademarks and/or registered trademarks of Biocompatibles UK Ltd. EKOS is a trademark and/or registered trademark of EKOS Corporation. GALIL, ICEROD, iTHAW, ICESPHERE, ICESEED, IceEDGE, VISUAL-ICE, ICEORCE, ICEPEARL, ICEFX are trademarks and/or registered trademarks of Galil Medical Ltd. PneumRx is a trademark and/or registered trademark of PneumRx, Inc. TheraSphere is a trademark and/or registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. Varithena is a trademark and/or registered trademark of Provensis Ltd. CroFab and DigiFab are trademarks and/or registered trademarks of BTG International, Inc. Voraxaze is a trademark and/or registered trademark of Protherics Medicines Development Ltd. SnakeBite911 and the SnakeBite911 logo are trademarks and/or registered trademarks of Protherics UK Ltd. MicroCross, CenterCross and MultiCross are trademarks and/or registered trademarks of Roxwood Medical, Inc. BTG Sentry is a trademark and/or registered trademark of Novate Medical Limited. Lemtrada is a trademark and/or registered trademark of Genzyme Corporation. Zytiga is a trademark and/or registered trademark of Johnson & Johnson. Biocompatibles UK Ltd, EKOS Corporation, Galil Medical Ltd, Novate Medical Limited, PneumRx, Inc., Protherics Medicines Development Ltd, Protherics UK Ltd, Provensis Ltd and Roxwood Medical Inc are all BTG International group companies.
 

For prescribing information, safety information, and/or product information, go to: bead-block | crofab | dcbead | dcbeadlumi | digifab | ekoscorp | galilmedical | lcbead | lcbeadlumi | lemtrada | pneumrx | therasphere | varithena | voraxaze | zytiga